Senior Management Appointments

Diaceutics PLC
11 July 2024
 

Diaceutics Makes Four Senior Management Appointments

VP Chief of Staff, VP of Human Resources, VP of Engagement Solutions and VP of Real-World Data

New roles will further strengthen management team and drive continued innovation, performance & growth at Diaceutics

 

Belfast and London, 11 July 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce four appointments to its executive team. These appointments are part of Diaceutics' commitment to strong governance and ensuring it has the structure in place to capitalise upon the growth in its market. The new Vice Presidents - Madeline Brown, Norma Thompson, Gosia Leitch, and Scott Phillips - bring a wealth of experience and expertise to their respective roles and will add significant strength to Diaceutics' leadership team and as it drives continued innovation, performance and growth.

Diaceutics CEO Ryan Keeling said, "Madeline, Norma, Gosia, and Scott are dynamic leaders whose extensive experience, vision and innovative approaches will be crucial in shaping Diaceutics' future performance and growth. As we continue to expand, their perspectives will be essential to helping us reach our full potential."

Madeline Brown, VP, Chief of Staff

Madeline Brown has been with Diaceutics since 2007, holding significant roles in finance and strategic project management. She will now lead the Chief Executive's Office, focusing on driving efficiencies and scalability.

Norma Thompson, VP of Human Resources

Norma Thompson joined Diaceutics in 2019 as Global Head of Human Resources. With over 30 years of experience, she brings extensive knowledge in HR management, talent development, and regulatory environments, essential for Diaceutics' global operations.

Gosia Leitch, VP of Engagement Solutions

Gosia Leitch has over 20 years of experience in diagnostics and pharma, including roles at Veracyte, Abbott, Qiagen, Bayer Healthcare and SC Johnson. She will drive engagement strategies connecting diagnostics with the broader healthcare ecosystem.

Scott Phillips, VP of Real-World Data

Scott Phillips brings over 12 years of experience in real-world data, product development, strategy consulting, and business development. Previously at Komodo Health and COTA Healthcare, he will enhance Diaceutics' data strategy and integration of real-world evidence.

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Enquiries:

Diaceutics PLC   


Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer  

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com



Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison, Nick Harland, Kate Hanshaw 




Alma Strategic Communications

Tel: +44(0)20 3405 0205 

Caroline Forde, Kinvara Verdon, Kieran Breheny  

diaceutics@almastrategic.com



 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Diaceutics (DXRX)
UK 100